Society for Industrial Microbiology and Biotechnology

simbhq.org

The Society for Industrial Microbiology and Biotechnology (SIMB) is a nonprofit, international association dedicated to the advancement of microbiological sciences, especially as they apply to industrial products, biotechnology, materials, and processes. Founded in 1949, SIMB promotes the exchange of scientific information through its meetings and publications, and serves as liaison among the specialized fields of microbiology. Membership in the Society is extended to all scientists and companies in the general field of microbiology.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact, Medical

KYMANOX ANNOUNCES ACQUISITION OF ANTERIS MEDICAL AND ANTERIS HELVETIA

Kymanox | February 06, 2023

news image

Kymanox, a leading life science-focused professional services firm, recently announced the acquisition of anteris medical GmbH and anteris helvetia AG (collectively anteris). Anteris specializes in assisting the commercialization and development of medical equipment, combination and in-vitro diagnostic products. This acquisition enables both firms to achieve their common organizational goal of geographic expansion while enhancing their service capabilities by offering clients a ...

Read More

BLUEBIRD BIO LAUNCHES FIRST GENE THERAPY FOR BETA THALASSEMIA IN GERMANY

Labiotech | January 15, 2020

news image

The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...

Read More

Industrial Impact

HOW MIGHT BIOMOLECULAR CONDENSATES REVOLUTIONIZE DRUG DISCOVERY? A PERSPECTIVE FROM DEWPOINT THERAPEUTICS

Dewpoint Therapeutics | August 18, 2022

news image

A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery. Condensates are membrane-less organelles that form dynamically throughout the cell via a process called phase separation. Over the last decade scientists have recognized the role of biomolecular condensates in cellular organization and disease, marking one of the most revolutionary areas of biology. In "Modulating biomolecular condensate...

Read More

Industrial Impact, Medical

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

Genprex, Inc. | December 16, 2022

news image

Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene ...

Read More
news image

Industrial Impact, Medical

KYMANOX ANNOUNCES ACQUISITION OF ANTERIS MEDICAL AND ANTERIS HELVETIA

Kymanox | February 06, 2023

Kymanox, a leading life science-focused professional services firm, recently announced the acquisition of anteris medical GmbH and anteris helvetia AG (collectively anteris). Anteris specializes in assisting the commercialization and development of medical equipment, combination and in-vitro diagnostic products. This acquisition enables both firms to achieve their common organizational goal of geographic expansion while enhancing their service capabilities by offering clients a ...

Read More
news image

BLUEBIRD BIO LAUNCHES FIRST GENE THERAPY FOR BETA THALASSEMIA IN GERMANY

Labiotech | January 15, 2020

The US company bluebird bio has launched the first gene therapy for the blood disorder transfusion-dependent beta thalassemia in the EU, with a hospital in Germany becoming its first qualified treatment center. Bluebird bio’s gene therapy, branded as Zynteglo, was given conditional market approval by the EU in June 2019. It was the first gene therapy approved to treat people over 12 years of age with all but the most severe form of transfusion-dependent beta thalassemia, a condition that n...

Read More
news image

Industrial Impact

HOW MIGHT BIOMOLECULAR CONDENSATES REVOLUTIONIZE DRUG DISCOVERY? A PERSPECTIVE FROM DEWPOINT THERAPEUTICS

Dewpoint Therapeutics | August 18, 2022

A new perspective published in Nature Reviews Drug Discovery examines the potential of biomolecular condensates to transform drug discovery. Condensates are membrane-less organelles that form dynamically throughout the cell via a process called phase separation. Over the last decade scientists have recognized the role of biomolecular condensates in cellular organization and disease, marking one of the most revolutionary areas of biology. In "Modulating biomolecular condensate...

Read More
news image

Industrial Impact, Medical

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

Genprex, Inc. | December 16, 2022

Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene ...

Read More